HRP20201087T1 - Supstituirani imidazo-hinolini kao nlrp3 modulatori - Google Patents
Supstituirani imidazo-hinolini kao nlrp3 modulatori Download PDFInfo
- Publication number
- HRP20201087T1 HRP20201087T1 HRP20201087TT HRP20201087T HRP20201087T1 HR P20201087 T1 HRP20201087 T1 HR P20201087T1 HR P20201087T T HRP20201087T T HR P20201087TT HR P20201087 T HRP20201087 T HR P20201087T HR P20201087 T1 HRP20201087 T1 HR P20201087T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- optionally substituted
- compound
- independently selected
- pharmaceutically acceptable
- Prior art date
Links
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 28
- 150000003839 salts Chemical class 0.000 claims 19
- 125000006413 ring segment Chemical group 0.000 claims 18
- 125000002947 alkylene group Chemical group 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 238000011319 anticancer therapy Methods 0.000 claims 5
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 5
- -1 mechloretamine Chemical compound 0.000 claims 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 claims 3
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 229940124650 anti-cancer therapies Drugs 0.000 claims 2
- 229960003852 atezolizumab Drugs 0.000 claims 2
- 229950002916 avelumab Drugs 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 201000010235 heart cancer Diseases 0.000 claims 2
- 208000024348 heart neoplasm Diseases 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 229960003989 tocilizumab Drugs 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- 102100022464 5'-nucleotidase Human genes 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 108010072524 BKT140 Proteins 0.000 claims 1
- 229940125565 BMS-986016 Drugs 0.000 claims 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010007275 Carcinoid tumour Diseases 0.000 claims 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 201000009047 Chordoma Diseases 0.000 claims 1
- 208000009798 Craniopharyngioma Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 108010092160 Dactinomycin Proteins 0.000 claims 1
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 108010069236 Goserelin Proteins 0.000 claims 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims 1
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- IVRXNBXKWIJUQB-UHFFFAOYSA-N LY-2157299 Chemical compound CC1=CC=CC(C=2C(=C3CCCN3N=2)C=2C3=CC(=CC=C3N=CC=2)C(N)=O)=N1 IVRXNBXKWIJUQB-UHFFFAOYSA-N 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 241000989747 Maba Species 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 229930192392 Mitomycin Natural products 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010070308 Refractory cancer Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000008938 Rhabdoid tumor Diseases 0.000 claims 1
- 206010073334 Rhabdoid tumour Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 206010043515 Throat cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 claims 1
- 206010046431 Urethral cancer Diseases 0.000 claims 1
- 206010046458 Urethral neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 229960000446 abciximab Drugs 0.000 claims 1
- 229930183665 actinomycin Natural products 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims 1
- 229960001220 amsacrine Drugs 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 208000021780 appendiceal neoplasm Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- 229960004669 basiliximab Drugs 0.000 claims 1
- 229950007843 bavituximab Drugs 0.000 claims 1
- 229960003270 belimumab Drugs 0.000 claims 1
- 229960000997 bicalutamide Drugs 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 229960000455 brentuximab vedotin Drugs 0.000 claims 1
- 229960001838 canakinumab Drugs 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 208000002458 carcinoid tumor Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229960003115 certolizumab pegol Drugs 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- 229960004630 chlorambucil Drugs 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 238000000315 cryotherapy Methods 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960002806 daclizumab Drugs 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960001251 denosumab Drugs 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 229960002224 eculizumab Drugs 0.000 claims 1
- 229960000284 efalizumab Drugs 0.000 claims 1
- 229950004647 emactuzumab Drugs 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000032099 esthesioneuroblastoma Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 claims 1
- 229960000752 etoposide phosphate Drugs 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 229960002074 flutamide Drugs 0.000 claims 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 229950000456 galunisertib Drugs 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 229960000578 gemtuzumab Drugs 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 229960001743 golimumab Drugs 0.000 claims 1
- 229960002913 goserelin Drugs 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 229960002193 histrelin Drugs 0.000 claims 1
- 108700020746 histrelin Proteins 0.000 claims 1
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 201000006866 hypopharynx cancer Diseases 0.000 claims 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims 1
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 229950011263 lirilumab Drugs 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- JJVZSYKFCOBILL-MKMRYRNGSA-N motixafortide Chemical compound NCCCC[C@@H]1NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCCN)NC1=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)c1ccc(F)cc1 JJVZSYKFCOBILL-MKMRYRNGSA-N 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 229960003816 muromonab-cd3 Drugs 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 229960002653 nilutamide Drugs 0.000 claims 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 229960002450 ofatumumab Drugs 0.000 claims 1
- 229960000470 omalizumab Drugs 0.000 claims 1
- 201000005443 oral cavity cancer Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 229960000402 palivizumab Drugs 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960003171 plicamycin Drugs 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 229960003876 ranibizumab Drugs 0.000 claims 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 229950007213 spartalizumab Drugs 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 1
- 229960001278 teniposide Drugs 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 229960004824 triptorelin Drugs 0.000 claims 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 claims 1
- 229950010095 ulocuplumab Drugs 0.000 claims 1
- 229950005972 urelumab Drugs 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 229960000653 valrubicin Drugs 0.000 claims 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 claims 1
- 229950001067 varlilumab Drugs 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Claims (22)
1. Spoj koje ima formulu (II):
[image]
ili njegova farmaceutski prihvatljiva sol, pri čemu:
R1 je nezavisno nesupstituirani C1-6 alkil, ili C(=O)Ra;
R2 je nezavisno H ili nesupstituirani C1-6 alkil;
R3 je:
(i) H;
(ii) nesupstituirani C1-2 alkil;
(iii) X-R8, pri čemu X je nerazgranati C1-6 alkilen, a R8 je -OH, C1-4 alkoksi, -C1-4 haloalkoksi, CO2Ra, ili -CONRcRd;
(iv) (C1-3 alkilen)-(C6-C10 aril), pri čemu aril je po izboru supstituirani sa od 1-3 supstituenta nezavisno odabrana od C1-6 alkila, C1-4 haloalkila, C1-4 alkoksi, i C1-4 haloalkoksi; ili
(v) (C1-3 alkilen)heteroaril koji uključuje od 5 do 6 atoma u prstenu, pri čemu od 1 do 4 atoma u prstenu su svaki nezavisno odabrani od N, N(Re), O, i S, i pri čemu heteroaril je po izboru supstituirani sa od 1 do 3 supstituenta nezavisno odabrana od C1-6 alkila, C1-4 haloalkila, C1-4 alkoksi, i C1-4 haloalkoksi;
R4 i R5 su svaki nezavisno odabrani od:
(i) H;
(ii) halo;
(iii) -(C0-3 alkilen)-C3-10 cikloalkila, pri čemu cikloalkil je po izboru supstituirani sa od 1 do 4 nezavisno odabrana Rf;
(iv) -(C0-3 alkilen)-heterociklila koji uključuje od 3 do 10 atoma u prstenu, pri čemu od 1 do 3 atoma u prstenu su svaki nezavisno odabrani od: N(Re), O, i S, pri čemu heterociklil je po izboru supstituirani sa od 1 do 4 Rf;
(v) -(C0-3 alkilen)-(C6-C10 arila) po izboru supstituisanog sa od 1 do 4 Rg;
(vi) -(C0-3 alkilen)-heteroarila koji uključuje od 5 do 10 atoma u prstenu, pri čemu od 1 do 4 atoma u prstenu su svaki nezavisno odabrani od: N, NH, O, i S, pri čemu heteroaril je po izboru supstituirani sa od 1 do 3 Rg;
(vii) C1-6 alkila po izboru supstituisanog sa od 1-2 nezavisno odabrana Rh; i
(viii) -(C0-3 alkilen)-C4-10 cikloalkenila, pri čemu cikloalkenil je po izboru supstituirani sa od 1 do 2 Rf;
Ra je:
(i) C1-6 alkil po izboru supstituirani sa od 1 do 2 Rh; ili
(ii) -(C0-3 alkilen)-C3-10 cikloalkil, pri čemu cikloalkil je po izboru supstituirani sa od 1 do 2 Rf;
(iii) -(C1-3 alkilen)-heterociklil koji uključuje od 3 do 10 atoma u prstenu, pri čemu od 1 do 3 atoma u prstenu su svaki nezavisno odabrani od N(Re), O, i S, pri čemu heterociklil je po izboru supstituirani sa od 1 do 4 nezavisno odabrana Rf;
(iv) -(C0-3 alkilen)-fenil po izboru supstituirani sa od 1 do 4 nezavisno odabrana Rg; ili
(v) -(C0-3 alkilen)-heteroaril koji uključuje od 5 do 10 atoma u prstenu, pri čemu od 1 do 4 atoma u prstenu su svaki nezavisno odabrani od N, N(Re), O, i S, pri čemu heteroaril je po izboru supstituirani sa od 1 do 3 nezavisno odabrana Rg;
pri svakom pojavljivanju Rc iRd je nezavisno H ili C1-4 alkil;
pri svakom pojavljivanju Re je nezavisno H ili C1-4 alkil;
pri svakom pojavljivanju Rf je nezavisno C1-6 alkil, C1-4 haloalkil, -OH, F, Cl, C1-4 alkoksi, C1-4 haloalkoksi, cijano, ili fenil po izboru supstituirani sa od 1 do 4 Rg;
pri svakom pojavljivanju Rg je nezavisno halo, cijano, C1-6 alkil, C1-4 haloalkil, C1-4 alkoksi, ili C1-4 haloalkoksi; i
pri svakom pojavljivanju Rh je nezavisno -OH, F, C1-4 alkoksi, C1-4 haloalkoksi, ili cijano.
2. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, pri čemu:
R3 je H, nesupstituirani C1-2 alkil, ili X-R8, pri čemu X je nerazgranati C2-6 alkilen, i R8 je CO2Ra, ili -CONRcRd;
R4 je nezavisno H ili halo;
R5 je nezavisno odabran od:
(i) H;
(ii) halo;
(iii) -(C0-3 alkilen)-C3-10 cikloalkila, pri čemu cikloalkil je po izboru supstituirani sa od 1 do 4 nezavisno odabrana Rf;
(iv) -(C0-3 alkilen)-heterociklila koji uključuje od 3 do 10 atoma u prstenu, pri čemu od 1 do 3 atoma u prstenu su svaki nezavisno odabrani od: N(Re), O, i S, pri čemu heterociklil je po izboru supstituirani sa od 1 do 4 Rf;
(v) -(C0-3 alkilen)-(C6-C10 arila) po izboru supstituisanog sa od 1 do 4 Rg;
(vi) -(C0-3 alkilen)-heteroarila koji uključuje od 5 do 10 atoma u prstenu, pri čemu od 1 do 4 atoma u prstenu su svaki nezavisno odabrani od: N, NH, O, i S, pri čemu heteroaril je po izboru supstituirani sa od 1 do 3 Rg;
(vii) C1-6 alkila po izboru supstituisanog sa od 1-2 nezavisno odabrana Rh; i
(viii) -(C0-3 alkilen)-C4-10 cikloalkenila, pri čemu cikloalkenil je po izboru supstituirani sa od 1 do 2 Rf.
3. Spoj prema bilo kojem od patentnih zahtjeva 1-2, ili njegova farmaceutski prihvatljiva sol, pri čemu:
R2 je nezavisno H ili nesupstituirani C1-3 alkil;
R3 je H, nesupstituirani C1-2 alkil, ili X-R8, pri čemu X je nerazgranati C2-4 alkilen, a R8 je CO2Ra, ili -CONRcRd;
R5 je nezavisno odabran od:
(i) C3-6 cikloalkila po izboru supstituisanog sa od 1 do 2 nezavisno odabrana Rf;
(ii) fenila po izboru supstituisanog sa od 1 do 3 Rg;
(iii) heteroarila koji uključuje od 5 do 6 atoma u prstenu, pri čemu od 1 do 3 atoma u prstenu su svaki nezavisno odabrani od: N, NH, O, i S, pri čemu heteroaril je po izboru supstituirani sa od 1 do 3 Rg;
(iv) C1-6 alkila po izboru supstituisanog sa od 1 do 2 nezavisno odabrana Rh; i
(v) C5-6 cikloalkenila po izboru supstituisanog sa od 1 do 2 Rf; i
Ra je H, C1-4 alkil po izboru supstituirani sa OH, C3-6 cikloalkil, fenil, ili heteroaril koji uključuje od 5 do 6 atoma u prstenu, pri čemu od 1 do 4 atoma u prstenu su svaki nezavisno odabrani od N, N(Re), O, i S.
4. Spoj prema bilo kojem od patentnih zahtjeva 1-3, pri čemu:
R2 je nezavisno H, CH3 ili CH2CH3;
R3 je H, CH3, ili -(CH2)3C(=O)OCH3;
R5 je nezavisno CH3, ciklopentil, ciklopentenil, fenil, pirazol-1-il, ili pirazol-3-il; i
Ra je H, CH3, CH2CH3, CH(CH3)2, C(CH3)3, ciklopropil, ili tiazolil.
5. Spoj prema bilo kojem od patentnih zahtjeva 1-4, ili njegova farmaceutski prihvatljiva sol, pri čemu:
R2 je nezavisno H, CH3 ili CH2CH3;
R3 je H ili CH3;
R5 je nezavisno CH3, ciklopentil, ciklopentenil, fenil, pirazol-1-il, ili pirazol-3-il; i
Ra je CH3, CH2CH3, CH(CH3)2, C(CH3)3, ili ciklopropil.
6. Spoj prema bilo kojem od patentnih zahtjeva 1-5, ili njegova farmaceutski prihvatljiva sol, pri čemu:
R1 je nezavisno CH3, CH2CH3, CH(CH3)2, C(CH3)3, ili C(=O)Ra;
R2 je nezavisno H, CH3 ili CH2CH3;
R3 je H;
R5 je nezavisno ciklopentil, ciklopentenil, fenil, pirazol-1-il, ili pirazol-3-il; i
Ra je CH3, CH2CH3, CH(CH3)2, C(CH3)3, ili ciklopropil.
7. Spoj prema patentnom zahtjevu 1, pri čemu spoj je
[image]
ili njegova farmaceutski prihvatljiva sol.
8. Spoj prema patentnom zahtjevu 1, pri čemu spoj je
[image]
9. Spoj prema patentnom zahtjevu 1, pri čemu spoj je
[image]
ili njegova farmaceutski prihvatljiva sol.
10. Spoj prema patentnom zahtjevu 1, pri čemu spoj je
[image]
11. Farmaceutska kompozicija koja sadrži spoj ili njegovu farmaceutski prihvatljivu sol prema bilo kojem od patentnih zahtjeva 1 do 10 i jedan ili više farmaceutski prihvatljivih ekscipijenasa.
12. Spoj ili njegova farmaceutski prihvatljiva sol u skladu sa bilo kojim od patentnih zahtjeva 1 do 10, ili farmaceutska kompozicija u skladu sa patentnim zahtjevom 11, za primjenu kao lijek.
13. Spoj ili njegova farmaceutski prihvatljiva sol u skladu sa bilo kojim od patentnih zahtjeva 1 do 10, ili farmaceutska kompozicija u skladu sa patentnim zahtjevom 11, za primjenu u liječenju raka kod subjekta.
14. Spoj, njegova farmaceutski prihvatljiva sol ili kompozicija za primjenu prema patentnom zahtjevu 13, pri čemu rak je odabran od akutne mijeloidne leukemija, adrenokortikalnog raka, Kaposijevog sarkoma, limfoma, analnog raka, raka apendiksa, teratoidnog/rabdoidnog tumora, raka bazalnih stanica, raka žučnih puteva, raka mjehura, raka kostiju, raka mozga, raka dojke, tumora bronhija, karcinoidnog tumora, kardijačnog tumora, raka grlića materice, hordoma, kronične limfocitne leukemije, kronične mijeloproliferativne neoplazme, raka kolona, kolorektalnog raka, kraniofaringioma, endometrijalnog raka, ependimoma, raka jednjaka, estezioneuroblastoma, Evingovog sindroma, raka oka, raka falopijevih cijevi, raka žučne vrećice, gastrointestinalnog karcinoidnog tumora, gastrointestinalnog stromalnog tumora, tumora germinativnih stanica, leukemije vlastastih stanica, raka glave i vrata, raka srca, raka jetre, hipofaringealnog raka, raka gušterače, raka bubrega, laringealnog raka, kronične mijeloične leukemije, raka usne i usne šupljine, raka pluća, melanoma, karcinoma Merkelovih stanica, mezotelioma, raka usta, oralnog raka, osteosarkoma, raka jajnika, raka penisa, faringealnog raka, raka prostate, rektalnog raka, raka žlijezda slinovnica, raka kože, raka tankog crijeva, sarkoma mekog tkiva, raka testisa, raka grla, raka štitnjače, raka uretre, raka maternice, raka vagine, i raka vulve.
15. Spoj, njegova farmaceutski prihvatljiva sol ili kompozicija za primjenu prema patentnom zahtjevu 13 ili patentnom zahtjevu 14, pri čemu rak je refraktorni rak.
16. Spoj, njegova farmaceutski prihvatljiva sol ili kompozicija za primjenu prema patentnom zahtjevu 13, pri čemu rak je odabran od raka dojke, raka kolona, rektalnog raka, kolorektalnog raka, raka gušterača, i raka prostate.
17. Spoj, njegova farmaceutski prihvatljiva sol ili kompozicija za primjenu prema bilo kojem od patentnih zahtjeva 13-16, pri čemu spoj ili kompozicija se administrira u kombinaciji sa jednom ili više dodatnih terapija protiv raka.
18. Spoj, njegova farmaceutski prihvatljiva sol ili kompozicija za primjenu prema patentnom zahtjevu 17, pri čemu jedna ili više dodatnih terapija protiv raka sadrži kirurgiju, radioterapiju, kemoterapiju, terapiju toksinima, imunoterapiju, krioterapiju ili gensku terapiju, ili kombinaciju istih.
19. Spoj, njegova farmaceutski prihvatljiva sol ili kompozicija za primjenu prema patentnom zahtjevu 17, pri čemu dodatna terapija protiv raka sadrži jedan ili više agenasa odabrana od cisplatina, karboplatina, mehloretamina, ciklofosfamida, klorambucila, ifosfamida, oksaliplatina, azatioprina, merkaptopurina, vinkristina, vinblastina, vinorelbina, vindesina, taksola, paklitaksela, docetaksela, irinotekana, amsakrina, etopozida, etopozid fosfata, tenipozida, aktinomicina, antraciklina, doksorubicina, daunorubicina, valrubicina, idarubicina, epirubicina, bleomicina, plikamicina, mitomicina, leuprolidina, goserelina, triptorelina, histrelina, bikalutamida, flutamida, nilutamida, abciksimaba, adalimumaba, alemtuzumaba, atlizumaba, baziliksimaba, belimumaba, bevacizumaba, brentuksimab vedotina, kanakinumaba, cetuksimaba, certolizumab pegola, daklizumaba, denozumaba, ekulizumaba, efalizumaba, gemtuzumaba, golimumaba, ibritumomab tiuksetana, infliksimaba, ipilimumaba, muromonab-CD3, natalizumaba, ofatumumaba, omalizumaba, palivizumaba, panitumumaba, ranibizumaba, rituksimaba, tocilizumaba, tozitumomaba, trastuzumaba, interleukina-2, indolamin 2,3-dioksigenaze, IL-10, transformirajućeg faktora rasta-β, CD39, CD73 adenozin-CD39-CD73, i CXCR4-CXCL12.
20. Spoj, njegova farmaceutski prihvatljiva sol ili kompozicija za primjenu prema patentnom zahtjevu 17, pri čemu dodatna terapija protiv raka sadrži jedan ili više agenasa odabrana od urelumaba, PF-05082566, MEDI6469, TRX518, varlilumaba, CP-870893, pembrolizumaba, nivolumaba, atezolizumaba, MEDI4736, avelumaba, PDR001, BMS-986016, MGA271, lirilumaba, IPH2201, emaktuzumaba, INCB024360, galunisertiba, ulokuplumaba, BKT140, bavituksimaba, CC-90002, bevacizumaba, i MNRP1685A.
21. Spoj, njegova farmaceutski prihvatljiva sol ili kompozicija za primjenu prema patentnom zahtjevu 17, pri čemu dodatna terapija protiv raka sadrži jedan ili više agenasa odabrana od nivolumaba, ipilimumaba, pembrolizumaba, atezolizumaba, i avelumaba.
22. Spoj, njegova farmaceutski prihvatljiva sol ili kompozicija za primjenu prema bilo kojem od patentnih zahtjeva 12-20 pri čemu spoj se administrira intratumoralno ili sustavno.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762460677P | 2017-02-17 | 2017-02-17 | |
US201762490881P | 2017-04-27 | 2017-04-27 | |
US201762573991P | 2017-10-18 | 2017-10-18 | |
EP18707612.0A EP3510034B1 (en) | 2017-02-17 | 2018-02-16 | Substituted imidazo-quinolines as nlrp3 modulators |
PCT/US2018/018484 WO2018152396A1 (en) | 2017-02-17 | 2018-02-16 | Substituted imidazo-quinolines as nlrp3 modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20201087T1 true HRP20201087T1 (hr) | 2020-10-30 |
Family
ID=61283434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20201087TT HRP20201087T1 (hr) | 2017-02-17 | 2020-07-13 | Supstituirani imidazo-hinolini kao nlrp3 modulatori |
Country Status (29)
Country | Link |
---|---|
US (4) | US10533005B2 (hr) |
EP (2) | EP3753938B1 (hr) |
JP (1) | JP7003143B6 (hr) |
KR (1) | KR102329062B1 (hr) |
CN (1) | CN110325534B (hr) |
AU (1) | AU2018221076B2 (hr) |
BR (1) | BR112019016625A2 (hr) |
CA (1) | CA3053949A1 (hr) |
CL (1) | CL2019002324A1 (hr) |
CO (1) | CO2019008932A2 (hr) |
CY (1) | CY1123305T1 (hr) |
DK (1) | DK3510034T3 (hr) |
ES (1) | ES2799900T3 (hr) |
HR (1) | HRP20201087T1 (hr) |
HU (1) | HUE050965T2 (hr) |
IL (1) | IL268640B (hr) |
LT (1) | LT3510034T (hr) |
ME (1) | ME03801B (hr) |
MX (1) | MX2019009788A (hr) |
MY (1) | MY194054A (hr) |
PE (1) | PE20191552A1 (hr) |
PL (1) | PL3510034T3 (hr) |
PT (1) | PT3510034T (hr) |
RS (1) | RS60548B1 (hr) |
SG (1) | SG11201907451XA (hr) |
SI (1) | SI3510034T1 (hr) |
TW (1) | TWI674261B (hr) |
WO (1) | WO2018152396A1 (hr) |
ZA (1) | ZA201906104B (hr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106397592A (zh) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
WO2018009916A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
BR112020000523A2 (pt) | 2017-07-14 | 2020-07-14 | Innate Tumor Immunity, Inc. | moduladores de nlrp3 |
US11203579B2 (en) | 2017-07-24 | 2021-12-21 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
JP2020531453A (ja) | 2017-08-15 | 2020-11-05 | インフレイゾーム リミテッド | Nlrp3阻害剤としてのスルホニルウレアおよびスルホニルチオウレア |
WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
UY37848A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
LT3697789T (lt) | 2017-10-18 | 2021-12-10 | Incyte Corporation | Kondensuoti imidazolo dariniai, pakeisti tretinėmis hidroksigrupėmis, kaip pi3k-gama inhibitoriai |
WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
EP3837015B1 (en) | 2018-08-16 | 2024-02-14 | Innate Tumor Immunity, Inc. | Imidazo[4,5-c]quinoline derived nlrp3-modulators |
ES2930171T3 (es) * | 2018-08-16 | 2022-12-07 | Innate Tumor Immunity Inc | Moduladores de NLRP3 derivados de imidazo[4,5-C]quinolina |
JP2021534180A (ja) | 2018-08-16 | 2021-12-09 | イネイト・テューマー・イミュニティ・インコーポレイテッドInnate Tumor Immunity, Inc. | 置換4−アミノ−1H−イミダゾ[4,5−c]キノリン化合物およびその製造の改良法 |
CN111253390B (zh) * | 2018-11-30 | 2023-10-03 | 四川科伦博泰生物医药股份有限公司 | 并环化合物、其制备方法及用途 |
EP3911641A1 (en) * | 2019-01-14 | 2021-11-24 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
KR20210114983A (ko) * | 2019-01-14 | 2021-09-24 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Nlrp3 조정제 |
CN113195469A (zh) | 2019-02-19 | 2021-07-30 | 四川科伦博泰生物医药股份有限公司 | 含氮并环化合物、其制备方法及用途 |
WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
US11744874B2 (en) * | 2019-12-20 | 2023-09-05 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof |
KR102409345B1 (ko) * | 2020-09-22 | 2022-06-16 | 가톨릭대학교 산학협력단 | Nlrp3 인플라마좀 억제제 및 이의 용도 |
CN116874340B (zh) * | 2023-07-10 | 2024-04-05 | 湖北航天化学技术研究所 | 一种苯基***类含能共晶化合物及其制备方法 |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US948029A (en) * | 1909-04-23 | 1910-02-01 | James Harvey Leffler | Reclining-chair. |
CA1271477A (en) | 1983-11-18 | 1990-07-10 | John F. Gerster | 1h-imidazo[4,5-c]quinolin-4-amines |
SG46492A1 (en) * | 1991-03-01 | 1998-02-20 | Minnesota Mining & Mfg | 1-Substituted 2-substituted 1H-imidazo [4,5-c] quinolin-4-amines |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
JPH1180156A (ja) | 1997-09-04 | 1999-03-26 | Hokuriku Seiyaku Co Ltd | 1−(置換アリール)アルキル−1h−イミダゾピリジン−4−アミン誘導体 |
ES2340745T3 (es) | 1998-12-23 | 2010-06-08 | Pfizer Inc. | Anticuerpos monoclonales humanos contra ctla-4. |
EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
GB0023008D0 (en) | 2000-09-20 | 2000-11-01 | Glaxo Group Ltd | Improvements in vaccination |
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
MXPA05006740A (es) | 2002-12-20 | 2005-10-05 | 3M Innovative Properties Co | Imidazoquinolinas arilo-sustituidas. |
WO2004071459A2 (en) | 2003-02-13 | 2004-08-26 | 3M Innovative Properties Company | Methods and compositions related to irm compounds and toll-like receptor 8 |
WO2005018555A2 (en) | 2003-08-14 | 2005-03-03 | 3M Innovative Properties Company | Lipid-modified immune response modifiers |
KR101106812B1 (ko) | 2003-08-27 | 2012-01-19 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 아릴옥시 및 아릴알킬렌옥시 치환된 이미다조퀴놀린 |
EA200600540A1 (ru) | 2003-09-05 | 2006-08-25 | Анадис Фармасьютикалз, Инк. | Введение лигандов tlr7 и их пролекарств для лечения инфекции вируса гепатита с |
JP4891088B2 (ja) | 2003-11-25 | 2012-03-07 | スリーエム イノベイティブ プロパティズ カンパニー | 置換されたイミダゾ環系および方法 |
TW200533352A (en) | 2003-12-04 | 2005-10-16 | 3M Innovative Properties Co | Sulfone substituted imidazo ring ethers |
WO2005094531A2 (en) | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
JP2007530579A (ja) | 2004-06-10 | 2007-11-01 | スリーエム イノベイティブ プロパティズ カンパニー | アミド置換イミダゾピリジン、イミダゾキノリン、およびイミダゾナフチリジン |
US20080015184A1 (en) * | 2004-06-14 | 2008-01-17 | 3M Innovative Properties Company | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines |
US8017779B2 (en) | 2004-06-15 | 2011-09-13 | 3M Innovative Properties Company | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
US20070259881A1 (en) | 2004-06-18 | 2007-11-08 | Dellaria Joseph F Jr | Substituted Imidazo Ring Systems and Methods |
US7915281B2 (en) | 2004-06-18 | 2011-03-29 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method |
MX2007003078A (es) | 2004-09-14 | 2007-05-16 | Novartis Vaccines & Diagnostic | Compuestos de imidazoquinolina. |
EP1835915A4 (en) | 2004-12-30 | 2010-02-24 | Coley Pharm Group Inc | IMMUNE REACTION MODIFIER FORMULATIONS AND RELATED METHODS |
JP2008532933A (ja) * | 2005-02-11 | 2008-08-21 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 置換イミダゾキノリン類および置換イミダゾナフチリジン類 |
EP1851218A2 (en) | 2005-02-23 | 2007-11-07 | 3M Innovative Properties Company | Hydroxyalkyl substituted imidazoquinoline compounds and methods |
WO2006098852A2 (en) | 2005-02-23 | 2006-09-21 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazoquinolines |
CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
WO2007079086A1 (en) | 2005-12-28 | 2007-07-12 | Coley Pharmaceutical Group, Inc. | Pyrazoloalkyl substituted imidazo ring compounds and methods |
DK2155743T3 (da) | 2007-05-08 | 2012-11-05 | Astrazeneca Ab | Imidazoquinoliner med immunmodulerende egenskaber |
EP3222634A1 (en) | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
EP2009002A1 (en) | 2007-06-21 | 2008-12-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New process for the manufacture of 1H-imidazo [4,5-c]-quinoline ring systems |
PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
WO2010088924A1 (en) * | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
KR101573109B1 (ko) | 2009-11-24 | 2015-12-01 | 메디뮨 리미티드 | B7―h1에 대한 표적화된 결합 물질 |
CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
US8728486B2 (en) | 2011-05-18 | 2014-05-20 | University Of Kansas | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds |
US9034336B2 (en) * | 2011-08-30 | 2015-05-19 | Regents Of The University Of Minnesota | Immunomodulators and immunomodulator conjugates |
LT2785375T (lt) | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antikūnai ir jų panaudojimas |
US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
CN115093480A (zh) | 2012-05-31 | 2022-09-23 | 索伦托药业有限公司 | 与pd-l1结合的抗原结合蛋白 |
EP2674170B1 (en) * | 2012-06-15 | 2014-11-19 | Invivogen | Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids |
US9295732B2 (en) | 2013-02-22 | 2016-03-29 | Invivogen | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists |
EP2992017B1 (en) | 2013-05-02 | 2020-11-18 | AnaptysBio, Inc. | Antibodies directed against programmed death-1 (pd-1) |
JP6453855B2 (ja) | 2013-05-18 | 2019-01-16 | アドゥロ バイオテック,インク. | 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法 |
JP6563906B2 (ja) | 2013-05-31 | 2019-08-21 | ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. | Pd−1に結合する抗原結合蛋白質 |
US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
AU2013400609B9 (en) | 2013-09-13 | 2020-03-05 | Beigene Switzerland Gmbh | Anti-PD1 antibodies and their use as therapeutics and diagnostics |
CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
US10654807B2 (en) | 2013-12-20 | 2020-05-19 | The University Of Kansas | Toll-like receptor 8 agonists |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
CN105233291A (zh) | 2014-07-09 | 2016-01-13 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
CN112587672A (zh) | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | 用于***的抗-pd-l1结合物 |
GB201418004D0 (en) | 2014-10-10 | 2014-11-26 | Isis Innovation | Polymer adjuvant |
CA2978942A1 (en) | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
MA48579A (fr) | 2015-09-01 | 2020-03-18 | Agenus Inc | Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci |
JP2018526013A (ja) | 2015-09-01 | 2018-09-13 | イネイト・テューマー・イミュニティ・インコーポレイテッドInnate Tumor Immunity, Inc. | 免疫または免疫抑制性サイトカインに対する抵抗性が増大した免疫細胞およびその使用 |
CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于***的抗-egfr组合 |
US10730871B2 (en) | 2016-01-28 | 2020-08-04 | Regents Of The University Of Minnesota | Immunomodulators and immunomodulator conjugates |
WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
CN111491362B (zh) | 2016-02-02 | 2023-10-24 | 华为技术有限公司 | 确定发射功率的方法、用户设备和基站 |
US10533007B2 (en) | 2016-04-19 | 2020-01-14 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
AU2017252640A1 (en) | 2016-04-19 | 2018-12-06 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
-
2018
- 2018-02-14 TW TW107105417A patent/TWI674261B/zh active
- 2018-02-16 CA CA3053949A patent/CA3053949A1/en active Pending
- 2018-02-16 JP JP2019544636A patent/JP7003143B6/ja active Active
- 2018-02-16 DK DK18707612.0T patent/DK3510034T3/da active
- 2018-02-16 RS RS20200830A patent/RS60548B1/sr unknown
- 2018-02-16 SI SI201830085T patent/SI3510034T1/sl unknown
- 2018-02-16 CN CN201880012493.7A patent/CN110325534B/zh active Active
- 2018-02-16 PT PT187076120T patent/PT3510034T/pt unknown
- 2018-02-16 HU HUE18707612A patent/HUE050965T2/hu unknown
- 2018-02-16 AU AU2018221076A patent/AU2018221076B2/en active Active
- 2018-02-16 MX MX2019009788A patent/MX2019009788A/es unknown
- 2018-02-16 BR BR112019016625A patent/BR112019016625A2/pt active Search and Examination
- 2018-02-16 EP EP20169634.1A patent/EP3753938B1/en active Active
- 2018-02-16 SG SG11201907451XA patent/SG11201907451XA/en unknown
- 2018-02-16 KR KR1020197026922A patent/KR102329062B1/ko active IP Right Grant
- 2018-02-16 ME MEP-2020-149A patent/ME03801B/me unknown
- 2018-02-16 US US15/898,258 patent/US10533005B2/en active Active
- 2018-02-16 ES ES18707612T patent/ES2799900T3/es active Active
- 2018-02-16 LT LTEP18707612.0T patent/LT3510034T/lt unknown
- 2018-02-16 EP EP18707612.0A patent/EP3510034B1/en active Active
- 2018-02-16 WO PCT/US2018/018484 patent/WO2018152396A1/en unknown
- 2018-02-16 MY MYPI2019004704A patent/MY194054A/en unknown
- 2018-02-16 PL PL18707612T patent/PL3510034T3/pl unknown
- 2018-02-16 PE PE2019001718A patent/PE20191552A1/es unknown
-
2019
- 2019-08-12 IL IL268640A patent/IL268640B/en unknown
- 2019-08-16 CO CONC2019/0008932A patent/CO2019008932A2/es unknown
- 2019-08-16 CL CL2019002324A patent/CL2019002324A1/es unknown
- 2019-09-16 ZA ZA2019/06104A patent/ZA201906104B/en unknown
- 2019-11-25 US US16/693,420 patent/US20200157096A1/en not_active Abandoned
-
2020
- 2020-07-13 HR HRP20201087TT patent/HRP20201087T1/hr unknown
- 2020-07-16 CY CY20201100649T patent/CY1123305T1/el unknown
-
2021
- 2021-05-06 US US17/313,319 patent/US11827632B2/en active Active
-
2023
- 2023-10-17 US US18/488,092 patent/US20240067649A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20201087T1 (hr) | Supstituirani imidazo-hinolini kao nlrp3 modulatori | |
JP2019513809A5 (hr) | ||
JP2020508302A5 (hr) | ||
Ying et al. | Lycorine inhibits breast cancer growth and metastasis via inducing apoptosis and blocking Src/FAK-involved pathway | |
ES2683356T3 (es) | Compuestos peptidomiméticos cíclicos como inmunomoduladores | |
CA2979145A1 (en) | 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators | |
US20210361649A1 (en) | Combination therapy with glutaminase inhibitors and immuno-oncology agents | |
BR112021004656A2 (pt) | conjugado fármaco-ligante de análogo exatecano, método para preparar o mesmo e aplicação do mesmo | |
CA2979142A1 (en) | Therapeutic cyclic compounds as immunomodulators | |
JP2020510032A5 (hr) | ||
RU2019114963A (ru) | Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo | |
RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
RU2017145026A (ru) | Соединение, ингибирующее brk | |
JP6245622B2 (ja) | Il−18と分子標的抗体とを併用する癌治療薬 | |
JP2020527139A5 (hr) | ||
AU2018386223A1 (en) | Small molecule degraders that recruit DCAFT15 | |
CN104661678A (zh) | 包含双重血管生成素-2/Dll4结合物和抗VEGF-R药剂的药物组合 | |
ES2263629T3 (es) | Farmaco para cancer de celulas espiteliales. | |
IL273387B2 (en) | Thylanstatin analogs | |
HRP20230659T1 (hr) | Sastavi i metode za osjetljivost na viruse | |
IL274920B2 (en) | Maytansinoid-based drug delivery systems | |
ES2789758T3 (es) | Uso de butilideneftalida | |
Ichimasa et al. | Correction: Artificial intelligence may help in predicting the need for additional surgery after endoscopic resection of T1 colorectal cancer | |
RU2385324C1 (ru) | Корректор паранеопластических повреждений и токсических эффектов цитостатической полихимиотерапии | |
RU2014119339A (ru) | 2-КАРБОКСАМИД ЦИКЛОАМИНО ПРОИЗВОДНЫЕ МОЧЕВИНЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ Hsp90 ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ |